Deferasirox price

Another group similar to leukemia patients is the thalassemia/and aplastic anemia group. Currently, there is no good treatment for this group. Transplantation is possible, but the risk is too great and the success rate is low. Most of them use regular blood transfusion + iron elimination treatment, which means that you need to go to the hospital for blood transfusion every month. The disadvantage of blood transfusion is that it directly leads to an increase in ferritin and iron accumulation! The harm is serious damage to the body's liver and heart, and this damage is irreversible! Three iron chelating drugs are currently approved to reduce iron burden, including ferroxamine (Novartis, Switzerland), ferroferrione (Apotex, Canada) and (Novartis, Switzerland).

Deferrioxamine (DFO) can combine with iron in ferritin or hemosiderin, convert it into ferrioxamine molecules and be excreted by the kidneys. The production of ferrioxamine can prevent the chemical reaction of iron, thereby reducing the formation of reactive oxygen species. Desferrioxamine can be injected subcutaneously or intravenously, and the dosage is 20~60mg/kg. Since the half-life is only 20 minutes, it requires continuous administration for a long time, which is more inconvenient. Both ferriprone and deferasirox can chelate intracellular iron and more directly remove iron that generates ROS than ferroxamine. Ordroferrione is an oral drug with a half-life of 2 to 3 hours. The dose is 50 to 100 mg/kg per day, taken orally in 3 times. It has many gastrointestinal side effects. The daily dosage of deferasirox dispersible tablets is 20~30 mg/kg, once a day, and has good clinical compliance, but it is expensive. In addition to chelating intracellular iron, deferasirox is also related to the increase in hepcidin, which can reduce iron absorption in intestinal cells, so the iron removal effect is better.

At present, deferiprone has been discontinued in many places, and the Swiss company Novartis mainly promotes Enregidarosirox. The current price of Enrig is 125mg/28 capsules, which is about $2,000 and is not covered by medical insurance. The dosage method is to take 20mg to 40mg of deferasirox for 1kg of body weight. The cost of a normal person weighing 60kg, taking 30mg/kg as an example, the cost of taking deferasirox for a month is more than 24,000$, which is difficult for ordinary patients to accept. Looking at India, the original version of deferasirox produced by Novartis in India is 400mg*30 tablets/box, priced at about RMB 700 equivalent; while the generic version of deferasirox produced by Cipla Pharmaceuticals in India is 500mg*30 tablets/box, priced at about RMB 500; both versions are more cost-effective than most versions on the market!